News

ETX-312 bien toléré à des doses élevées lors d’études de toxicologie conformes aux normes BPL Fabrication du lot destiné à l’essai clinique achevée avec succès conformément aux normes BPF Soumission d ...
In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation ...
Walmart Canada est la principale entreprise partenaire de la Croix-Rouge canadienne. Sa clientèle, ses associées et associés et elle ont permis d’amasser plus de 77 millions de dollars au profit de la ...
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that ...
The Canadian Red Cross, in collaboration with Walmart Canada, is pleased to announce its annual giving campaign in support of emergency response. For the month of July, Walmart customers across Canada ...
Goldman Sachs & Co. LLC, Guggenheim Securities, TD Cowen, Cantor and Oppenheimer & Co. are acting as joint book-running managers for the public offering.
The Epilepsy Foundation of America (EFA) is proud to announce the appointment of Daryl Drabinsky, distinguished communications and corporate affairs executive, to its National Board of Directors.
Lisaftoclax is a proprietary, novel orally administered small-molecule Bcl-2 selective inhibitor developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the ...
Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares ...
Completed ahead of schedule, the new facility is designed to anticipate growth as it more than doubles Tevogen’s previous ...
The closing of the offering is expected to occur on or about July 10, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be ...